Pirh21 (7B9) Mouse mAb
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, IHC, ICC |
---|---|
Primary Accession | Q96PM5 |
Reactivity | Rat |
Host | Mouse |
Clonality | Monoclonal Antibody |
Calculated MW | 30110 Da |
Gene ID | 25898 |
---|---|
Other Names | ARNIP; CHIMP; RNF199; RCHY1 |
Dilution | WB~~1:1000 IHC~~1:100~500 ICC~~N/A |
Name | RCHY1 |
---|---|
Function | E3 ubiquitin-protein ligase that mediates ubiquitination of target proteins, including p53/TP53, TP73, HDAC1 and CDKN1B (PubMed:16914734, PubMed:17721809, PubMed:18006823, PubMed:19043414, PubMed:19483087, PubMed:21994467). Mediates ubiquitination and degradation of p53/TP53; preferentially acts on tetrameric p53/TP53 (PubMed:19043414, PubMed:19483087). Catalyzes monoubiquitinates the translesion DNA polymerase POLH (PubMed:21791603). Involved in the ribosome-associated quality control (RQC) pathway, which mediates the extraction of incompletely synthesized nascent chains from stalled ribosomes: RCHY1 acts downstream of NEMF and recognizes CAT tails associated with stalled nascent chains, leading to their ubiquitination and degradation (PubMed:33909987). |
Cellular Location | Nucleus. Nucleus speckle. Cytoplasm |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Swiss-Prot Acc.Q96PM5.Pirh 2 (P53 induced RING-H2 protein), also known as RCHY1, it forms dimers through its N- and C-terminus in cells. The Pirh2 has ubiquitin-protein ligase activity and it binds with p53 and promotes the ubiquitin-mediated proteosomal degradation of p53. The Pirh2 is oncogenic because loss of p53 function contributes directly to malignant tumor development. Pirh2 expression decreases the level of p53, and a decrease of endogenous Pirh2 expression increases p53 levels. Pirh2 is therefore considered, together with MDM2, to act as a negative regulator of p53 function.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.